Research summaries
Long-form editorial maps of the literature. Animal vs human tiers labeled explicitly.
CT-G32 (SCO-940): four-receptor preclinical data and sponsor disclosures
Editorial map of Scohia/Celltrion CT-G32 (SCO-940) TIDES Europe 2026 disclosures: four-receptor concept, rat preclinical comparisons, evidence limits vs human retatrutide trials.
UBT251 phase 2 in China: Cell Metabolism trial map (not a retatrutide comparison)
Editorial summary of the UBT251 triple-agonist phase 2 paper (DOI 10.1016/j.cmet.2026.09.021, NCT07177469): design, LS mean weight change at 24 weeks, limits, and why social cross-trial numbers mislead.
BPC-157 research: animal models, sparse human reports, and what is still unknown
An evidence map for stable gastric pentadecapeptide BPC-157 — preclinical cytoprotection literature, limited human case reports, and regulatory context. Educational only.
Retatrutide phase 2 obesity trial: published human data and regulatory context
Summary of the NEJM phase 2 retatrutide trial (LY3437943, NCT04881760): eligibility, endpoints, weight outcomes, separate diabetes trial, and FDA-sourced status notes.
TB-500 and thymosin beta-4: why research names are not interchangeable
TB-500 is a research peptide label tied to a thymosin β4 fragment; FDA-reviewed thymosin beta-4 drug programs are a separate evidence line. Educational comparison with primary sources.